Über uns
Freeline Therapeutics GmbH
Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the U.K. and has operations in Germany and the U.S. Freeline was listed on NASDAQ 7th August 2020.
Our gene therapy treatment builds upon the pioneering, world renowned work by the Freeline founder, Professor Amit Nathwani. His award-winning scientific work has already been life changing for patients with Haemophilia B by making gene therapy safe, effective and reliable. Our Freeline Haemophilia B and Fabry disease programmes are already in the clinic. Our broad pipeline allows more opportunities to change lives by providing liver-directed gene therapy as a life-long and potentially curative treatment.
